{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:26:28Z","timestamp":1784075188551,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1124\/jpet.115.231456","type":"journal-article","created":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T04:49:24Z","timestamp":1457066964000},"page":"293-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice"],"prefix":"10.1016","volume":"357","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-8180","authenticated-orcid":false,"given":"Alejandro","family":"Mart\u00ednez-\u00c1guila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"P\u00e9rez de Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Pintor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.231456_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-079X.2009.00702.x","article-title":"5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit","volume":"47","author":"Alarma-Estrany","year":"2009","journal-title":"J Pineal Res"},{"key":"10.1124\/jpet.115.231456_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/jpet.110.178319","article-title":"Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits","volume":"337","author":"Alarma-Estrany","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.231456_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neulet.2011.02.056","article-title":"Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse","volume":"494","author":"Alcantara-Contreras","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1124\/jpet.115.231456_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/ng794","article-title":"Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA\/2J mice","volume":"30","author":"Anderson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.115.231456_bib5","first-page":"66","article-title":"Glaucoma\u2013a eye disorder: its causes, risk factor, prevention and medication","volume":"1","author":"Bhowmik","year":"2012","journal-title":"Pharm J"},{"key":"10.1124\/jpet.115.231456_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.survophthal.2006.12.008","article-title":"Staging functional damage in glaucoma: review of different classification methods","volume":"52","author":"Brusini","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1124\/jpet.115.231456_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/FPC.0b013e32834910d1","article-title":"Regulation of ocular adrenoceptor genes expression by 5-MCA-NAT: implications for glaucoma treatment","volume":"21","author":"Crooke","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/jpet.115.231456_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1517\/17460441.2012.714769","article-title":"Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential","volume":"7","author":"Crooke","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.115.231456_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-079X.2011.00938.x","article-title":"Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5-MCA-NAT","volume":"52","author":"Crooke","year":"2012","journal-title":"J Pineal Res"},{"key":"10.1124\/jpet.115.231456_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1124\/jpet.112.202036","article-title":"Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma","volume":"346","author":"Crooke","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.231456_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1096\/fasebj.12.12.1211","article-title":"Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms","volume":"12","author":"Dubocovich","year":"1998","journal-title":"FASEB J"},{"key":"10.1124\/jpet.115.231456_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10633-009-9194-5","article-title":"Electrophysiological deficits in the retina of the DBA\/2J mouse","volume":"119","author":"Harazny","year":"2009","journal-title":"Doc Ophthalmol"},{"key":"10.1124\/jpet.115.231456_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.114.218263","article-title":"Melatonin receptors trigger cAMP production and inhibit chloride movements in nonpigmented ciliary epithelial cells","volume":"352","author":"Huete-Toral","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.231456_bib14","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1213\/ane.0b013e3181907ebe","article-title":"Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia","volume":"108","author":"Ismail","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1124\/jpet.115.231456_bib15","first-page":"951","article-title":"Essential iris atrophy, pigment dispersion, and glaucoma in DBA\/2J mice","volume":"39","author":"John","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.115.231456_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1017\/S0952523805225130","article-title":"Inherited glaucoma in DBA\/2J mice: pertinent disease features for studying the neurodegeneration","volume":"22","author":"Libby","year":"2005","journal-title":"Vis Neurosci"},{"key":"10.1124\/jpet.115.231456_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejphar.2012.12.009","article-title":"Melatonin analogue agomelatine reduces rabbit\u2019s intraocular pressure in normotensive and hypertensive conditions","volume":"701","author":"Mart\u00ednez-\u00c1guila","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.115.231456_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(95)00870-5","article-title":"2-[125I]iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites","volume":"301","author":"Molinari","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.115.231456_bib19","doi-asserted-by":"crossref","first-page":"31311","DOI":"10.1074\/jbc.M005141200","article-title":"Identification of the melatonin-binding site MT3 as the quinone reductase 2","volume":"275","author":"Nosjean","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.115.231456_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exer.2014.02.022","article-title":"Assessment of inner retina dysfunction and progressive ganglion cell loss in a mouse model of glaucoma","volume":"122","author":"P\u00e9rez de Lara","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.115.231456_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/opo.12189","article-title":"Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients","volume":"35","author":"Pescosolido","year":"2015","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1124\/jpet.115.231456_bib22","series-title":"Autonomic Nervous System: Ophthalmic Control","author":"Pintor","year":"2009"},{"key":"10.1124\/jpet.115.231456_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-2999(01)00864-0","article-title":"Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits","volume":"416","author":"Pintor","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.115.231456_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.bjp.0705118","article-title":"Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor","volume":"138","author":"Pintor","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.231456_bib25","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"Quigley","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/jpet.115.231456_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/02713688109001822","article-title":"Circadian rhythm in intraocular pressure: a rabbit model","volume":"1","author":"Rowland","year":"1981","journal-title":"Curr Eye Res"},{"key":"10.1124\/jpet.115.231456_bib27","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1167\/iovs.07-0483","article-title":"Longitudinal evaluation of retinal ganglion cell function and IOP in the DBA\/2J mouse model of glaucoma","volume":"48","author":"Saleh","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.115.231456_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.ijg.0000133150.44686.0b","article-title":"Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes","volume":"13","author":"Serle","year":"2004","journal-title":"J Glaucoma"},{"key":"10.1124\/jpet.115.231456_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/bmj.2.5914.298","article-title":"Prazosin: preliminary report and comparative studies with other antihypertensive agents","volume":"2","author":"Stokes","year":"1974","journal-title":"BMJ"},{"issue":"Suppl 5","key":"10.1124\/jpet.115.231456_bib30","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/IJG.0b013e3182934bb4","article-title":"Is the melatonin receptor type 1 involved in the pathogenesis of glaucoma?","volume":"22","author":"Tosini","year":"2013","journal-title":"J Glaucoma"},{"key":"10.1124\/jpet.115.231456_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-079X.2010.00746.x","article-title":"Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand","volume":"48","author":"Vincent","year":"2010","journal-title":"J Pineal Res"},{"key":"10.1124\/jpet.115.231456_bib32","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1021\/jm00086a018","article-title":"Novel naphthalenic ligands with high affinity for the melatonin receptor","volume":"35","author":"Yous","year":"1992","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.231456_bib33","doi-asserted-by":"crossref","first-page":"31240","DOI":"10.1074\/jbc.M502641200","article-title":"Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma","volume":"280","author":"Zhou","year":"2005","journal-title":"J Biol Chem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.231456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:44:52Z","timestamp":1739994292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524193135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0022356524193135"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.231456","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.231456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}